urea has been researched along with sorafenib in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM | 1 |
| Bar-Eli, M; Melnikova, VO | 1 |
| Chen, KF; Chen, PJ; Chen, WL; Cheng, AL; Hsu, CY; Huang, JW; Shiau, CW; Tai, WT | 1 |
| Huang, W; Jiang, F; Li, S; Li, Y; Yao, S; Yao, Z; Yu, S; Yuan, S; Zhan, W; Zhao, Y | 1 |
| Conroy, MD; Liu, AX; Liu, C; Schmidt, ES; Sviripa, V; Truong, J; Watt, DS; Zhang, W | 1 |
| Chen, XG; Huang, HH; Jin, B; Li, Y; Lu, CS; Ma, C; Tang, K; Yin, DL | 1 |
| Baar, K; Carraway, KL; Gilda, JE; Gomes, AV; Hammock, BD; Hwang, SH; Leon, LJ; Patton, A; Wecksler, AT; Weiss, RH; Wettersten, HI | 1 |
| Bai, Y; Guo, X; Kang, H; Lu, L; Lu, M; Qu, Z; Ren, Z; Shi, L; Song, T; Wang, H; Wang, X; Yang, W; Yang, Y; Ye, SL; Zhou, W; Zhu, K | 1 |
| Abdel-Maksoud, MS; El-Gamal, MI; Gamal El-Din, MM; Oh, CH; Yoo, KH | 1 |
| Hammock, BD; Hwang, SH; Li, H; Liao, J; Liu, JY; Wecksler, AT; Yang, GY; Yang, J; Yang, Y | 1 |
| Cheng, HJ; Chu, YY; Li, G; Li, WB; Sun, CJ; Tian, ZH; Zhao, JC | 1 |
| Barclay, W; Frise, R; Gravenstein, I; Herrmann, A; Imai-Matsushima, A; Karlas, A; Lesch, M; Luckner, M; Martin-Sancho, L; Meyer, M; Meyer, TF; Raftery, M; Schönrich, G; Sieben, C; Weege, F; Welke, RW | 1 |
| Cho, SB; Hong, YM; Hwang, SY; Jang, BK; Jang, ES; Jang, JY; Jung, YK; Kim, DY; Kim, HJ; Kim, JH; Kim, MY; Lee, HW; Lee, JH; Lee, YS; Seo, YS; Yim, HJ; Yoon, KT | 1 |
| Chang, Y; Cho, EJ; Kim, YJ; Lee, JH; Lee, YB; Yoon, JH; Yu, SJ | 1 |
| Hu, SH; Lien, RY; Lu, LC; Lu, SF; Tung, HH; Wu, SL | 1 |
3 trial(s) available for urea and sorafenib
| Article | Year |
|---|---|
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Emulsions; Female; Hand-Foot Syndrome; Humans; Incidence; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Skin; Sorafenib; Surveys and Questionnaires; Treatment Outcome; Urea; Young Adult | 2015 |
Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Quality of Life; Skin; Skin Cream; Skin Diseases; Sorafenib; Urea | 2020 |
Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Urea | 2022 |
12 other study(ies) available for urea and sorafenib
| Article | Year |
|---|---|
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea | 2008 |
Searching for the Achilles' heel of melanoma cells: new treatment modalities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Clinical Trials as Topic; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Melanoma; Niacinamide; Organoselenium Compounds; Phenylurea Compounds; Pyridines; Pyrimethamine; Skin Neoplasms; Sorafenib; Treatment Outcome; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.
Topics: Amides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Structure-Activity Relationship; Sulfonamides; Urea | 2011 |
Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Structure-Activity Relationship; Urea | 2012 |
Fluorinated N,N'-diarylureas as AMPK activators.
Topics: AMP-Activated Protein Kinases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Halogenation; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Urea | 2013 |
Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Niacinamide; Phenylurea Compounds; Solubility; Sorafenib; Structure-Activity Relationship; Urea | 2013 |
Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.
Topics: Adamantane; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Autophagy; Benzamides; Caspases; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mitochondrial Membranes; Niacinamide; Oxidative Stress; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Sorafenib; Urea | 2014 |
Synthesis and broad-spectrum antiproliferative activity of diarylamides and diarylureas possessing 1,3,4-oxadiazole derivatives.
Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Niacinamide; Oxadiazoles; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship; Urea | 2015 |
Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzoates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epoxide Hydrolases; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Genetic Predisposition to Disease; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; Niacinamide; Oxylipins; Pancreatic Neoplasms; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Tumor Burden; Urea | 2016 |
Rational drug design of indazole-based diarylurea derivatives as anticancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer-Aided Design; Drug Design; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Indazoles; Molecular Docking Simulation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib; Structure-Activity Relationship; Urea | 2017 |
RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals.
Topics: A549 Cells; Active Transport, Cell Nucleus; Antiviral Agents; Host-Pathogen Interactions; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Orthomyxoviridae; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; RNA Interference; RNA Viruses; RNA, Small Interfering; Sorafenib; Urea; Virus Replication | 2019 |
CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Cytoprotection; Disease Models, Animal; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Mice; Sorafenib; Transfection; Urea | 2020 |